I found this abstract that talks about the inhibition of FTO's...

I found this abstract that talks about the inhibition of FTO's influence on cancer progression specifically in a hypoxic environment: https://pubmed.ncbi.nlm.nih.gov/39304899/



It got me looking at hypoxia and from what I can gather, the aggressiveness, resistance to therapy and difficulty in treating some cancers can be attributed in some degree to the level of hypoxia.

A lot of cancers exhibit hypoxia and pancreatic cancer in particular is noted for extreme hypoxia. An exception is prostate cancer which is not hypoxic and is slow growing, especially in the early stages. Later stage pancreatic cancer can become hypoxic and if and when it does it becomes more agressive. From my limited understanding of the papers I read on the effect of FTO inhibition on different cancers, it looks like FTO inhibition in pancreatic cancer actually leads to a worse outcome since FTO has some positive effects in this particular cancer most of the time.

So I am wondering if hypoxia is something that in part determines how effective bisantrene can be, and therefore could it be measured in the trial?

Sorry @Mason14 if you have already covered this in your video, I checked the threads it hasn't been mentioned much in relation to FTO.